CHARLOTTESVILLE, Va., Nov. 7, 2013 /PRNewswire/ -- Safer and more effective anticancer drugs may soon be developed thanks to a Small Business Innovation Research contract recently awarded to HemoShear by the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH). HemoShear, LLC, is the pharmaceutical industry's leading developer of the most advanced human biology systems for applications in drug research and development.
Anticancer drugs continue to suffer the highest rate of failure in clinical trials as compared with other therapeutic areas. According to the NCI, "There is a critical need to improve the accuracy of preclinical drug efficacy screening and testing through the development of [laboratory-based] culture systems that more effectively mimic the [human] environment. Systems to properly recreate the tumor microenvironment are lacking and [are] essential to advance the discovery and development of effective anticancer agents."
HemoShear's contract with the National Cancer Institute will support the development of human cell-based systems that accurately replicate the biology of lung and pancreatic tumors, two of the deadliest groups of tumors. "Lung and pancreatic cancer are terrible diseases that have no effective treatments," said Dr. Brian Wamhoff, HemoShear co-founder and Vice President of R&D. "We are using our innovative science to enable the discovery of new treatments for cancer patients. While billions of dollars continue to be spent on researching and developing new cancer therapies, their success rates in clinical trials are not improving. Imagine a human tumor on the laboratory bench that responds to new therapies as if it were in the human body.
|SOURCE HemoShear, LLC|
Copyright©2012 PR Newswire.
All rights reserved